I'll provide to performance. most since the third significant Thanks contributor strong starting was Okay. that now our molecular few business a Ron. update with quarter business our
performed increased the year continue as it to well of exceptionally during business in XXX% did quarter. the molecular Our in compared to the the QX again and in trend expect last this quarter we Revenues year. fourth first half here
of this largest quarter in compared Our our business, year prior our of primary growth QX commercial a customers. from result new many continued year. driver higher the and addition grew customers of sales of genomics as both Revenues the was to sequentially and to
of XX sales XX prior higher of year-to-date XX year molecular customers customers over the period compared to During purchases our top top XX last and the year. the generated our when quarter, increased
offerings. higher also business expanded our adoption genomics of Our services sales international benefited from and
prior from Our QX. year growth international business doubled sequential delivered the and quarter double-digit from
in the customers services business quarter. well new prior of to the business. as and Growth performance strong our year from business continues from quarter the record as service quarter drive the revenue a existing Our had GenoFIND from quarter acquisition double the delivering of increase another the fourfold third previous
and we pharmacogenomics during pilot, focusing for on the collection a Finally, quarter of services benefit statewide plan. group won customized new provide devices GenoFIND retirement to third significant a members our contract
program, a expand While a much the believe is under of this involving a retirees pilot number into plan. could broader opportunity, large this we
third business deliver academic and purchasers benefit growing and driving commercial a in are acquisition the which from of repeat year prior in other than microbiome doubling testing. quarter. existing new A of the pharmacogenomic the similar In plans, during ongoing to of are a purchasing addition, quarter, the the of revenues. past with revenue markets current to represented seeking On largest continued customers performance that our it for The microbiome customers to perform revenues could adoption years. two business, quarters more customers each both customers strong repeat two microbiome serve during the from as model statewide strong by number
In services the microbiome the our offerings are offerings as international quarters which both customers revenues HCV processing very commercial for microbiome academic substantially now the XXXX. strong the are addition, HIV over our and up all interest self-test main year sales. in In and optimistic Aggregate three the sample short, and In million part for about $X.X continue totaled products recorded exceeds and $X.X area, XXX% of analysis. drivers business. this leverage during continue to of quarter our end-to-end services million, prior the infectious future for first microbiome we be and disease see the to
largely international supply continued agreements, for countrywide initiatives in QX growth strong which its Our elimination government demand to related we've HCV highlighted. previously and business due
We XXX% increased government previously compared a As to renew the supply revenues Ron mentioned our arrangement. quarter. existing our to with prior-year large ongoing noted, customer QX discussions our
time, likely customer well in volume been at has some be renewed the that excess would contract. contract from of existing a this the For indication the
and when in their to set because testing. pressures. HCV to prior testing in end, told although budget in adopt government test given solution with We that intends solution discussions these a of needs, decided a on participated were our cost. this and until our to week Hepatitis the broader to technical the distributor in along support tender components a based straightforward winning this move change provided we even We've this contract the solely even last that as which This Late test meet the extremely not came was best customer laboratory decided C The a its successful period lines our program repeated for the the next us surprise testing it that of continued pricing process to offered all viable discussions transition the We in apparently arrangement. for laboratory-based customer. economically the bidder requiring that to customer from development more customer engaged news made renewal quite renewal HCV rapid to received performed unfortunately, an just well negotiations being been feedback advised Our was of this to and our model with discussions, expansion close supply discussions surprising. a very that us. testing and of tender HCV
believe that C based broad test and especially in rural of to occurs role continue the testing our We Hepatitis areas programs much-needed our can where much will of rapid Hepatitis a perform remote testing or country. C in
is since understand in Our for our testing OraQuick those laboratory. test more this product. this continue locations, view a involved officials fluid samples some that blood for share ideal process government a deliver to to oral HCV and requires to collection advocate laboratory We and
of strong program testing in other large-scale interest remained that market marketing for the So, this we're test. might globally our continuing treatment the level in HCV and -- screening in our meantime, In programs. government OraQuick participate with for the we HCV hopeful we're and future periods, product again
are programs oral remain international believe tests support focused we the about for business our increasingly participation optimistic international And quality value cost, will Hepatitis HCV programs. fluid high Although a C on overall, we model. in proposition these rapid
new grew HCV expansion by This side, of the XX% existing of programs was testing domestic our and the the prior-year business driven to quarter. On programs. growth compared initiation
the past Louisiana. Alabama our companies. hospital and ways individuals community-based programs. Given offset partially be South Rouge HCV and mentioned initiatives. areas Columbia from to and cities diagnosed the to in are with HCV challenges public work we populations by were continued linked testing among Tuskegee and office that OraSure, Baton finding goal Carolina, channel to is in initial physician business. include a small hard settings, This and to organizations growth other This our Southern is declines targeted collaboration in pharmaceutical markets advocacy to The Despite into New domestically, Birmingham testing funding care. health certain resources On groups expand treatment calls, can so prevalence, high Orleans, reach urban and cities organizations
the orders self-testing, nine past prevalence international the this tested in our results populations indicate During with months, other tested. to strong of professional been to Asia. working phase a HIV and program On product business primarily third to during quarter growth XXX% compared quarter. in in was driven prior of STAR Project We're international cities. by turned have expand individuals into sales X the increase HIV our the thousands with a year of almost self-testing performance XX% our and This these with product for of HIV the Africa along
of the pleased STAR received is During self-test start a expects shipping our also X organizations deploy countries in shipped this we other Outside for discussions last our the of call we and We're year-end, several we The that this order million I'm expected prequalification in order report STAR or Project we large an product additional NGO beginning be receipt to X to indicated nongovernmental as product disclosed. of that countries. the to prior up non-STAR is expect initiate be that fourth will see to trigger quarter. fund in apparent the to to large Phase WHO self-testing and self-testing West previously in with for organization we in Africa. to that HIV HIV funding are scale Program, of
continues behind receipt not to our are expected orders prequalification. indication of WHO until build another self-testing that is momentum XXXX, HIV this Although following
been see those with and Project. also agreement Support of our STAR more go made are covered beginning continues countries Charitable execution arrangement the XX by outside authorities well. The with Our covered relevant from Gates the Foundation by very we under to orders to of sizable countries aware the agreement in the the health Gates have
HIV continues self-testing to business contributor a nicely believe grow in we disease business this infectious our our will be and business So, significant to periods. future
seen in same The again, front, fourth continued there the in the factors and domestic largely in and our in funding current our business. our These much are this the the as On competition, health trending the testing our CDCs The laboratory the equipment, movement HIV HIV automated more by quarter use business we've pressures third change periods. our generation include sales HCV price nothing the the for underlying had the is of HIV an timing on severe prior in than market decline of in was growth HIV decline revenues domestic conditions weather public domestic the impact orders. Once recent also self-test businesses. offset in quarter. for
affect order the our and HIV expected past indicated future receive technical the was our indicated for product. to use. for further to sputum factors OMNIgene for that This Consequently, of a regarding WHO its operational released guidance we positive. indicated support OMNIgene We will will sales data we Sputum required various issue in was this This procurement of market to continue some periods. in expect is recommendation supports review that transport which allow prior organizations a interested challenging pilots report routine In including view inconclusive. work solutions WHO domestic month is data calls as research, for report tuberculosis, the to sizes. Sputum doing funding WHO parties The that of report
to the test. relate routine working our our with additional use we'll Zika and that OMNIgene support forward we'll In address diseases, to to Sputum the recommendation to I area only be for one item of emerging working data required generate WHO Going the of a that with define to our have data. new customers be and
will XXXX. submission like to previously expand effort our And manufacturing remain test, unfortunately the and made demand FDA ongoing progress EUA the meet submit the the final and successfully really of commercializing increasing address likely area into capacity is products. be We've of obtaining technical QX a approval or in challenges We authorization from for this this we We to EUA to number because year areas. expect to our I'd indicated of with in this have pushed good that use test. to committed emergency for
now Our with be equipment new end two This our design third or automated line second with the shifts. full is automated OraQuick is the contractor our is Thailand for and year in on mid-XXXX has is operational and and now phase The installed by to in XXXX. also OraQuick of has the Work running progressed installed. also the supplier early expected operation now additional equipment capacity at been is the assembly nicely. line production progressing
We validation to be regulatory early equipment by XXXX. this expect received in of completed with year-end approvals
Our Thailand non-U.S. contractor non-CE HIV OraQuick product developing countries. is used and supply the for primarily Mark, in
March is planning A also for of expansion Given capacity now two early functional part signed we're next than was in completed for being no new in warehouse X, our XXXX in with April seeing in of our that the recently additional should lines finally, late automated provide and or Construction business, collection capacity. January lease operation we're year. line as the yet February in assembly and a by and to facility project. for a our we expected be fully into in XXXX. be strength Oragene built expected XXXX DNA of delivery is scheduled X warehouse Bethlehem April later for near self-testing new to And of December put kits additional or build line automated is Thailand mid-October to another operation
very summary was in strong. So, performance QX our
we solid around will our globe, to expect through remainder expect priorities. we to our investments with the before and to will our demands meet capitalize momentum. We business XXXX of focus us the and consistent manufacturing and enter the many continue We're to future use with strategic the on our XXXX the necessary opportunities in products making in on continue capacity trends expanding of recent the
take you can we that, questions. with your And if proceed. Question-and-Answer would So, operator, now Session
